Novartis-backed GenSight gets cash for gene therapy launch – FierceBiotech
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … |
GoDanRiver.com |
After two stem cell transplants and several rounds of chemo, ‘now he’s just like a normal 2-year-old’
GoDanRiver.com Dr. William Clark is associate professor of medicine and attending physician at Virginia Commonwealth University Massey Cancer Center Stem Cell Transplantation Program. Clark said the procedure is used for conditions including multiple myeloma, … |
News-Medical.net |
Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer
News-Medical.net The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the negative effects of the disease on patients’ quality of life. Both head and neck cancer and the treatment for it can have a huge … 10 updates in immunotherapy research – HealioHealio Tumour characteristics could predict immunotherapy success in lung …Cancer Research UK Lung Cancer Treatment Research: Immunotherapy Drug Caused Less Severe Side Effects Than ChemotherapyMedical Daily Medgadget (blog) –Japan Today –Daily Mail all 8 news articles » |
|
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations
P&T Community Among the considerations when selecting a cancer immunotherapy to treat a patient are the treatment goals, patient’s status, type of tumor, speed of disease progression, and potential efficacy and adverse effects (AEs). Because patients with cancer … |